Information Provided By:
Fly News Breaks for January 28, 2020
Jan 28, 2020 | 07:35 EDT
RBC Capital analyst Kennen MacKay raised his price target on Acceleron to $72 after the release of "surprise positive" sotatercept data in PAH. The analyst believes that sotatercept's initial findings suggest that its use adds to the standard of care, and he adds its potential impact to his model that assumes peak sales of as high as $1.6B. MacKay still keeps his Sector Perform rating on Acceleron.
News For XLRN From the Last 2 Days
There are no results for your query XLRN